# Internal carotid artery involvement and stroke risk in Takayasu arteritis: a case–control study

**Authors:** Hulya Odabasi Bukun, Ugur Uygunoglu, Esra Firat Senturk, Guzin Duru, Osman Kızılkılıç, Sinem Nihal Esatoglu, Melike Melikoglu, Emire Seyahi

PMC · DOI: 10.1007/s00296-026-06075-7 · Rheumatology International · 2026-02-07

## TL;DR

This study finds that internal carotid artery involvement and male gender are strong risk factors for stroke in Takayasu arteritis, leading to severe disability and high mortality.

## Contribution

The study identifies ICA involvement and male gender as independent predictors of stroke in TA, highlighting gaps in current treatment effectiveness.

## Key findings

- ICA involvement is strongly associated with stroke in Takayasu arteritis patients.
- Male patients have a significantly higher risk of stroke compared to female patients.
- Stroke often occurs as the first manifestation of TA and leads to severe disability and mortality.

## Abstract

Stroke represents a major complication in Takayasu arteritis (TA). We aimed to determine clinical characteristics and neurological outcomes in TA patients with stroke compared to those without. We retrospectively analyzed 35 patients (27F/8 M) with documented stroke to 50 consecutive patients (47F/3 M) without stroke followed by the Istanbul University-Cerrahpasa Medical Faculty. Demographic data, clinical manifestations, arterial involvement patterns, treatments, and neurological outcomes were evaluated. Disability was assessed using the Expanded Disability Status Scale (EDSS), Barthel Index, and Modified Rankin Scale. Mean age at diagnosis among patients with stroke and non-stroke was similar (38.5 ± 10.7 vs. 35.6 ± 11.6 years). The mean age at stroke was 43.1 ± 10.3 years. Patients with stroke were more likely to be male (22.9% vs. 6.0%, p = 0.023). Strokes were predominantly ischemic (91.4%), affecting anterior circulation (82.8%) with left hemisphere predominance (72.4%). Internal carotid artery (ICA) involvement was significantly associated with stroke (right ICA: 51.4% vs 18.0%, p = 0.001; left ICA: 37.1% vs 18.0%, p = 0.047), while abdominal aorta involvement seemed to be protective (20.0% vs 42.0%, p = 0.028). Male gender (OR = 5.70, p = 0.038) and any ICA involvement (OR = 5.98, p = 0.004) were identified as independent predictors of stroke. Importantly, 40% experienced stroke as the initial TA manifestation. Among those developing stroke after TA diagnosis, 85.7% were already receiving immunosuppression and 47.6% antiplatelet therapy. Stroke patients demonstrated significant disability (mean EDSS: 3.63 ± 3.36 vs 0.02 ± 0.14, p < 0.001) and 11.4% mortality, median 5 years after stroke. Male patients and those with ICA involvement face the highest risk for stroke in TA. Long-term consequences are devastating with increased mortality, severe disability and high recurrence rates. The failure of immunosuppressive therapy to prevent stroke in the majority of treated patients, combined with substantial perioperative mortality, stress the inadequacy of current management strategies.

## Linked entities

- **Diseases:** Takayasu arteritis (MONDO:0017991), stroke (MONDO:0005098)

## Full-text entities

- **Genes:** TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}
- **Diseases:** intracranial arterial vasculitis (MESH:D020765), epilepsy (MESH:D004827), artery (MESH:D012078), subarachnoid hemorrhage (MESH:D013345), hearing loss (MESH:D034381), IBD (MESH:D015212), asthma (MESH:D001249), hemorrhage (MESH:D006470), Neurological disability (MESH:D009069), fibrosis (MESH:D005355), neurological sequelae of (MESH:D009422), rheumatoid arthritis (MESH:D001172), fatigue (MESH:D005221), stenosis (MESH:D003251), Speech disturbance (MESH:D013064), neuro-degenerative disorders (MESH:D019636), hypertension (MESH:D006973), extracranial (MESH:D018241), Hemorrhagic stroke (MESH:D000083302), cerebral infarction (MESH:D002544), WM infarcts (MESH:D007238), cerebrovascular complications (MESH:D002561), thrombosis (MESH:D013927), CCA occlusion (MESH:D002340), pericarditis (MESH:D010493), interstitial lung disease (MESH:D017563), TA (MESH:D013625), Post-stroke (MESH:D020521), thromboembolism (MESH:D013923), mono-ocular blindness (MESH:C536238), hyperlipidemia (MESH:D006949), ischemic (MESH:D002545), visual disturbances (MESH:D014786), Facial paralysis (MESH:D005158), Inflammatory (MESH:D007249), hidradenitis suppurativa (MESH:D017497), AS (MESH:D013167), dyslipidemia (MESH:D050171), cerebral venous sinus thrombosis (MESH:D012851), glomerulonephritis (MESH:D005921), leukomalacia (MESH:D007969), amyloidosis (MESH:D000686), large-vessel vasculitis (MESH:D014657), anterior circulation infarcts (MESH:D020520), TIA (MESH:D002546), endothelial (MESH:D005642), hemiparesis (MESH:D010291), intracranial hemorrhage (MESH:D020300), granulomatous (MESH:D013968), TMB (MESH:D001766), aneurysm rupture (MESH:D017542), patent foramen ovale (MESH:D054092), vertigo (MESH:D014717), ischemic heart disease (MESH:D017202), multiple sclerosis (MESH:D009103), Vascular damage (MESH:D057772), disease (MESH:D004194), calcification (MESH:D002114), chronic obstructive pulmonary disease (MESH:D029424), vasculitic injury (MESH:D014947)
- **Chemicals:** antiplatelet (-), leflunomide (MESH:D000077339), methylprednisolone (MESH:D008775), prednisolone (MESH:D011239), cyclophosphamide (MESH:D003520), Infliximab (MESH:D000069285), water (MESH:D014867), methotrexate (MESH:D008727), golimumab (MESH:C529000), azathioprine (MESH:D001379), rituximab (MESH:D000069283), adalimumab (MESH:D000068879), certolizumab (MESH:D000068582), tocilizumab (MESH:C502936)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12882948/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12882948/full.md

---
Source: https://tomesphere.com/paper/PMC12882948